Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study
The combination of bortezomib, lenalidomide, and dexamethasone is a highly effective therapy for newly diagnosed multiple myeloma. Ixazomib is an investigational, oral, proteasome inhibitor with promising anti-myeloma effects and low rates of peripheral neuropathy. In a phase 1/2 trial we aimed to a...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Kumar, Shaji K [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2014 |
|---|
| Umfang: |
10 |
|---|
| Übergeordnetes Werk: |
Enthalten in: My - Citovsky, Vitaly ELSEVIER, 2019, London |
|---|---|
| Übergeordnetes Werk: |
volume:15 ; year:2014 ; number:13 ; pages:1503-1512 ; extent:10 |
| Links: |
|---|
| DOI / URN: |
10.1016/S1470-2045(14)71125-8 |
|---|
| Katalog-ID: |
ELV022459634 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV022459634 | ||
| 003 | DE-627 | ||
| 005 | 20230623164000.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1470-2045(14)71125-8 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000673.pica |
| 035 | |a (DE-627)ELV022459634 | ||
| 035 | |a (ELSEVIER)S1470-2045(14)71125-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 570 |q VZ |
| 084 | |a BIODIV |q DE-30 |2 fid | ||
| 084 | |a 35.70 |2 bkl | ||
| 084 | |a 42.12 |2 bkl | ||
| 100 | 1 | |a Kumar, Shaji K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study |
| 264 | 1 | |c 2014 | |
| 300 | |a 10 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a The combination of bortezomib, lenalidomide, and dexamethasone is a highly effective therapy for newly diagnosed multiple myeloma. Ixazomib is an investigational, oral, proteasome inhibitor with promising anti-myeloma effects and low rates of peripheral neuropathy. In a phase 1/2 trial we aimed to assess the safety, tolerability, and activity of ixazomib in combination with lenalidomide and dexamethasone in newly diagnosed multiple myeloma. | ||
| 700 | 1 | |a Berdeja, Jesus G |4 oth | |
| 700 | 1 | |a Niesvizky, Ruben |4 oth | |
| 700 | 1 | |a Lonial, Sagar |4 oth | |
| 700 | 1 | |a Laubach, Jacob P |4 oth | |
| 700 | 1 | |a Hamadani, Mehdi |4 oth | |
| 700 | 1 | |a Stewart, A Keith |4 oth | |
| 700 | 1 | |a Hari, Parameswaran |4 oth | |
| 700 | 1 | |a Roy, Vivek |4 oth | |
| 700 | 1 | |a Vescio, Robert |4 oth | |
| 700 | 1 | |a Kaufman, Jonathan L |4 oth | |
| 700 | 1 | |a Berg, Deborah |4 oth | |
| 700 | 1 | |a Liao, Eileen |4 oth | |
| 700 | 1 | |a Di Bacco, Alessandra |4 oth | |
| 700 | 1 | |a Estevam, Jose |4 oth | |
| 700 | 1 | |a Gupta, Neeraj |4 oth | |
| 700 | 1 | |a Hui, Ai-Min |4 oth | |
| 700 | 1 | |a Rajkumar, Vincent |4 oth | |
| 700 | 1 | |a Richardson, Paul G |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n The Lancet Publ. Group |a Citovsky, Vitaly ELSEVIER |t My |d 2019 |g London |w (DE-627)ELV003173852 |
| 773 | 1 | 8 | |g volume:15 |g year:2014 |g number:13 |g pages:1503-1512 |g extent:10 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/S1470-2045(14)71125-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a FID-BIODIV | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 35.70 |j Biochemie: Allgemeines |q VZ |
| 936 | b | k | |a 42.12 |j Biophysik |q VZ |
| 951 | |a AR | ||
| 952 | |d 15 |j 2014 |e 13 |h 1503-1512 |g 10 | ||
| author_variant |
s k k sk skk |
|---|---|
| matchkey_str |
kumarshajikberdejajesusgniesvizkyrubenlo:2014----:aeyntlrbltoiaoiaoapoesmihbtrnobntowtlnldmdadeaehsniptetwtpeiulut |
| hierarchy_sort_str |
2014 |
| bklnumber |
35.70 42.12 |
| publishDate |
2014 |
| allfields |
10.1016/S1470-2045(14)71125-8 doi GBV00000000000673.pica (DE-627)ELV022459634 (ELSEVIER)S1470-2045(14)71125-8 DE-627 ger DE-627 rakwb eng 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Kumar, Shaji K verfasserin aut Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study 2014 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The combination of bortezomib, lenalidomide, and dexamethasone is a highly effective therapy for newly diagnosed multiple myeloma. Ixazomib is an investigational, oral, proteasome inhibitor with promising anti-myeloma effects and low rates of peripheral neuropathy. In a phase 1/2 trial we aimed to assess the safety, tolerability, and activity of ixazomib in combination with lenalidomide and dexamethasone in newly diagnosed multiple myeloma. Berdeja, Jesus G oth Niesvizky, Ruben oth Lonial, Sagar oth Laubach, Jacob P oth Hamadani, Mehdi oth Stewart, A Keith oth Hari, Parameswaran oth Roy, Vivek oth Vescio, Robert oth Kaufman, Jonathan L oth Berg, Deborah oth Liao, Eileen oth Di Bacco, Alessandra oth Estevam, Jose oth Gupta, Neeraj oth Hui, Ai-Min oth Rajkumar, Vincent oth Richardson, Paul G oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:15 year:2014 number:13 pages:1503-1512 extent:10 https://doi.org/10.1016/S1470-2045(14)71125-8 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 15 2014 13 1503-1512 10 |
| spelling |
10.1016/S1470-2045(14)71125-8 doi GBV00000000000673.pica (DE-627)ELV022459634 (ELSEVIER)S1470-2045(14)71125-8 DE-627 ger DE-627 rakwb eng 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Kumar, Shaji K verfasserin aut Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study 2014 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The combination of bortezomib, lenalidomide, and dexamethasone is a highly effective therapy for newly diagnosed multiple myeloma. Ixazomib is an investigational, oral, proteasome inhibitor with promising anti-myeloma effects and low rates of peripheral neuropathy. In a phase 1/2 trial we aimed to assess the safety, tolerability, and activity of ixazomib in combination with lenalidomide and dexamethasone in newly diagnosed multiple myeloma. Berdeja, Jesus G oth Niesvizky, Ruben oth Lonial, Sagar oth Laubach, Jacob P oth Hamadani, Mehdi oth Stewart, A Keith oth Hari, Parameswaran oth Roy, Vivek oth Vescio, Robert oth Kaufman, Jonathan L oth Berg, Deborah oth Liao, Eileen oth Di Bacco, Alessandra oth Estevam, Jose oth Gupta, Neeraj oth Hui, Ai-Min oth Rajkumar, Vincent oth Richardson, Paul G oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:15 year:2014 number:13 pages:1503-1512 extent:10 https://doi.org/10.1016/S1470-2045(14)71125-8 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 15 2014 13 1503-1512 10 |
| allfields_unstemmed |
10.1016/S1470-2045(14)71125-8 doi GBV00000000000673.pica (DE-627)ELV022459634 (ELSEVIER)S1470-2045(14)71125-8 DE-627 ger DE-627 rakwb eng 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Kumar, Shaji K verfasserin aut Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study 2014 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The combination of bortezomib, lenalidomide, and dexamethasone is a highly effective therapy for newly diagnosed multiple myeloma. Ixazomib is an investigational, oral, proteasome inhibitor with promising anti-myeloma effects and low rates of peripheral neuropathy. In a phase 1/2 trial we aimed to assess the safety, tolerability, and activity of ixazomib in combination with lenalidomide and dexamethasone in newly diagnosed multiple myeloma. Berdeja, Jesus G oth Niesvizky, Ruben oth Lonial, Sagar oth Laubach, Jacob P oth Hamadani, Mehdi oth Stewart, A Keith oth Hari, Parameswaran oth Roy, Vivek oth Vescio, Robert oth Kaufman, Jonathan L oth Berg, Deborah oth Liao, Eileen oth Di Bacco, Alessandra oth Estevam, Jose oth Gupta, Neeraj oth Hui, Ai-Min oth Rajkumar, Vincent oth Richardson, Paul G oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:15 year:2014 number:13 pages:1503-1512 extent:10 https://doi.org/10.1016/S1470-2045(14)71125-8 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 15 2014 13 1503-1512 10 |
| allfieldsGer |
10.1016/S1470-2045(14)71125-8 doi GBV00000000000673.pica (DE-627)ELV022459634 (ELSEVIER)S1470-2045(14)71125-8 DE-627 ger DE-627 rakwb eng 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Kumar, Shaji K verfasserin aut Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study 2014 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The combination of bortezomib, lenalidomide, and dexamethasone is a highly effective therapy for newly diagnosed multiple myeloma. Ixazomib is an investigational, oral, proteasome inhibitor with promising anti-myeloma effects and low rates of peripheral neuropathy. In a phase 1/2 trial we aimed to assess the safety, tolerability, and activity of ixazomib in combination with lenalidomide and dexamethasone in newly diagnosed multiple myeloma. Berdeja, Jesus G oth Niesvizky, Ruben oth Lonial, Sagar oth Laubach, Jacob P oth Hamadani, Mehdi oth Stewart, A Keith oth Hari, Parameswaran oth Roy, Vivek oth Vescio, Robert oth Kaufman, Jonathan L oth Berg, Deborah oth Liao, Eileen oth Di Bacco, Alessandra oth Estevam, Jose oth Gupta, Neeraj oth Hui, Ai-Min oth Rajkumar, Vincent oth Richardson, Paul G oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:15 year:2014 number:13 pages:1503-1512 extent:10 https://doi.org/10.1016/S1470-2045(14)71125-8 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 15 2014 13 1503-1512 10 |
| allfieldsSound |
10.1016/S1470-2045(14)71125-8 doi GBV00000000000673.pica (DE-627)ELV022459634 (ELSEVIER)S1470-2045(14)71125-8 DE-627 ger DE-627 rakwb eng 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Kumar, Shaji K verfasserin aut Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study 2014 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The combination of bortezomib, lenalidomide, and dexamethasone is a highly effective therapy for newly diagnosed multiple myeloma. Ixazomib is an investigational, oral, proteasome inhibitor with promising anti-myeloma effects and low rates of peripheral neuropathy. In a phase 1/2 trial we aimed to assess the safety, tolerability, and activity of ixazomib in combination with lenalidomide and dexamethasone in newly diagnosed multiple myeloma. Berdeja, Jesus G oth Niesvizky, Ruben oth Lonial, Sagar oth Laubach, Jacob P oth Hamadani, Mehdi oth Stewart, A Keith oth Hari, Parameswaran oth Roy, Vivek oth Vescio, Robert oth Kaufman, Jonathan L oth Berg, Deborah oth Liao, Eileen oth Di Bacco, Alessandra oth Estevam, Jose oth Gupta, Neeraj oth Hui, Ai-Min oth Rajkumar, Vincent oth Richardson, Paul G oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:15 year:2014 number:13 pages:1503-1512 extent:10 https://doi.org/10.1016/S1470-2045(14)71125-8 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 15 2014 13 1503-1512 10 |
| language |
English |
| source |
Enthalten in My London volume:15 year:2014 number:13 pages:1503-1512 extent:10 |
| sourceStr |
Enthalten in My London volume:15 year:2014 number:13 pages:1503-1512 extent:10 |
| format_phy_str_mv |
Article |
| bklname |
Biochemie: Allgemeines Biophysik |
| institution |
findex.gbv.de |
| dewey-raw |
570 |
| isfreeaccess_bool |
false |
| container_title |
My |
| authorswithroles_txt_mv |
Kumar, Shaji K @@aut@@ Berdeja, Jesus G @@oth@@ Niesvizky, Ruben @@oth@@ Lonial, Sagar @@oth@@ Laubach, Jacob P @@oth@@ Hamadani, Mehdi @@oth@@ Stewart, A Keith @@oth@@ Hari, Parameswaran @@oth@@ Roy, Vivek @@oth@@ Vescio, Robert @@oth@@ Kaufman, Jonathan L @@oth@@ Berg, Deborah @@oth@@ Liao, Eileen @@oth@@ Di Bacco, Alessandra @@oth@@ Estevam, Jose @@oth@@ Gupta, Neeraj @@oth@@ Hui, Ai-Min @@oth@@ Rajkumar, Vincent @@oth@@ Richardson, Paul G @@oth@@ |
| publishDateDaySort_date |
2014-01-01T00:00:00Z |
| hierarchy_top_id |
ELV003173852 |
| dewey-sort |
3570 |
| id |
ELV022459634 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV022459634</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623164000.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1470-2045(14)71125-8</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000673.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV022459634</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1470-2045(14)71125-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.70</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kumar, Shaji K</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The combination of bortezomib, lenalidomide, and dexamethasone is a highly effective therapy for newly diagnosed multiple myeloma. Ixazomib is an investigational, oral, proteasome inhibitor with promising anti-myeloma effects and low rates of peripheral neuropathy. In a phase 1/2 trial we aimed to assess the safety, tolerability, and activity of ixazomib in combination with lenalidomide and dexamethasone in newly diagnosed multiple myeloma.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Berdeja, Jesus G</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Niesvizky, Ruben</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lonial, Sagar</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Laubach, Jacob P</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hamadani, Mehdi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stewart, A Keith</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hari, Parameswaran</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Roy, Vivek</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vescio, Robert</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kaufman, Jonathan L</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Berg, Deborah</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liao, Eileen</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Di Bacco, Alessandra</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Estevam, Jose</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gupta, Neeraj</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hui, Ai-Min</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rajkumar, Vincent</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Richardson, Paul G</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">The Lancet Publ. Group</subfield><subfield code="a">Citovsky, Vitaly ELSEVIER</subfield><subfield code="t">My</subfield><subfield code="d">2019</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV003173852</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:13</subfield><subfield code="g">pages:1503-1512</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1470-2045(14)71125-8</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.70</subfield><subfield code="j">Biochemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.12</subfield><subfield code="j">Biophysik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">2014</subfield><subfield code="e">13</subfield><subfield code="h">1503-1512</subfield><subfield code="g">10</subfield></datafield></record></collection>
|
| author |
Kumar, Shaji K |
| spellingShingle |
Kumar, Shaji K ddc 570 fid BIODIV bkl 35.70 bkl 42.12 Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study |
| authorStr |
Kumar, Shaji K |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV003173852 |
| format |
electronic Article |
| dewey-ones |
570 - Life sciences; biology |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study |
| topic |
ddc 570 fid BIODIV bkl 35.70 bkl 42.12 |
| topic_unstemmed |
ddc 570 fid BIODIV bkl 35.70 bkl 42.12 |
| topic_browse |
ddc 570 fid BIODIV bkl 35.70 bkl 42.12 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
j g b jg jgb r n rn s l sl j p l jp jpl m h mh a k s ak aks p h ph v r vr r v rv j l k jl jlk d b db e l el b a d ba bad j e je n g ng a m h amh v r vr p g r pg pgr |
| hierarchy_parent_title |
My |
| hierarchy_parent_id |
ELV003173852 |
| dewey-tens |
570 - Life sciences; biology |
| hierarchy_top_title |
My |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV003173852 |
| title |
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study |
| ctrlnum |
(DE-627)ELV022459634 (ELSEVIER)S1470-2045(14)71125-8 |
| title_full |
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study |
| author_sort |
Kumar, Shaji K |
| journal |
My |
| journalStr |
My |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science |
| recordtype |
marc |
| publishDateSort |
2014 |
| contenttype_str_mv |
zzz |
| container_start_page |
1503 |
| author_browse |
Kumar, Shaji K |
| container_volume |
15 |
| physical |
10 |
| class |
570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Kumar, Shaji K |
| doi_str_mv |
10.1016/S1470-2045(14)71125-8 |
| dewey-full |
570 |
| title_sort |
safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study |
| title_auth |
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study |
| abstract |
The combination of bortezomib, lenalidomide, and dexamethasone is a highly effective therapy for newly diagnosed multiple myeloma. Ixazomib is an investigational, oral, proteasome inhibitor with promising anti-myeloma effects and low rates of peripheral neuropathy. In a phase 1/2 trial we aimed to assess the safety, tolerability, and activity of ixazomib in combination with lenalidomide and dexamethasone in newly diagnosed multiple myeloma. |
| abstractGer |
The combination of bortezomib, lenalidomide, and dexamethasone is a highly effective therapy for newly diagnosed multiple myeloma. Ixazomib is an investigational, oral, proteasome inhibitor with promising anti-myeloma effects and low rates of peripheral neuropathy. In a phase 1/2 trial we aimed to assess the safety, tolerability, and activity of ixazomib in combination with lenalidomide and dexamethasone in newly diagnosed multiple myeloma. |
| abstract_unstemmed |
The combination of bortezomib, lenalidomide, and dexamethasone is a highly effective therapy for newly diagnosed multiple myeloma. Ixazomib is an investigational, oral, proteasome inhibitor with promising anti-myeloma effects and low rates of peripheral neuropathy. In a phase 1/2 trial we aimed to assess the safety, tolerability, and activity of ixazomib in combination with lenalidomide and dexamethasone in newly diagnosed multiple myeloma. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA |
| container_issue |
13 |
| title_short |
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study |
| url |
https://doi.org/10.1016/S1470-2045(14)71125-8 |
| remote_bool |
true |
| author2 |
Berdeja, Jesus G Niesvizky, Ruben Lonial, Sagar Laubach, Jacob P Hamadani, Mehdi Stewart, A Keith Hari, Parameswaran Roy, Vivek Vescio, Robert Kaufman, Jonathan L Berg, Deborah Liao, Eileen Di Bacco, Alessandra Estevam, Jose Gupta, Neeraj Hui, Ai-Min Rajkumar, Vincent Richardson, Paul G |
| author2Str |
Berdeja, Jesus G Niesvizky, Ruben Lonial, Sagar Laubach, Jacob P Hamadani, Mehdi Stewart, A Keith Hari, Parameswaran Roy, Vivek Vescio, Robert Kaufman, Jonathan L Berg, Deborah Liao, Eileen Di Bacco, Alessandra Estevam, Jose Gupta, Neeraj Hui, Ai-Min Rajkumar, Vincent Richardson, Paul G |
| ppnlink |
ELV003173852 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/S1470-2045(14)71125-8 |
| up_date |
2024-07-06T22:02:32.359Z |
| _version_ |
1803868808004239360 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV022459634</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623164000.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1470-2045(14)71125-8</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000673.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV022459634</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1470-2045(14)71125-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.70</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kumar, Shaji K</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The combination of bortezomib, lenalidomide, and dexamethasone is a highly effective therapy for newly diagnosed multiple myeloma. Ixazomib is an investigational, oral, proteasome inhibitor with promising anti-myeloma effects and low rates of peripheral neuropathy. In a phase 1/2 trial we aimed to assess the safety, tolerability, and activity of ixazomib in combination with lenalidomide and dexamethasone in newly diagnosed multiple myeloma.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Berdeja, Jesus G</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Niesvizky, Ruben</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lonial, Sagar</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Laubach, Jacob P</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hamadani, Mehdi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stewart, A Keith</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hari, Parameswaran</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Roy, Vivek</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vescio, Robert</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kaufman, Jonathan L</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Berg, Deborah</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liao, Eileen</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Di Bacco, Alessandra</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Estevam, Jose</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gupta, Neeraj</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hui, Ai-Min</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rajkumar, Vincent</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Richardson, Paul G</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">The Lancet Publ. Group</subfield><subfield code="a">Citovsky, Vitaly ELSEVIER</subfield><subfield code="t">My</subfield><subfield code="d">2019</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV003173852</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:13</subfield><subfield code="g">pages:1503-1512</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1470-2045(14)71125-8</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.70</subfield><subfield code="j">Biochemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.12</subfield><subfield code="j">Biophysik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">2014</subfield><subfield code="e">13</subfield><subfield code="h">1503-1512</subfield><subfield code="g">10</subfield></datafield></record></collection>
|
| score |
7.4012938 |